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a b s t r a c t
We describe the case of an 18-yr-old male under anti-TNF treatment for Crohn’s disease for more than 8
months. He developed fever and biological inﬂammatory syndromewithout absolutely no accompanying
sign or symptom or paraclinical abnormality despite extensive work-up performed in the context of his
immunocompromised state. Symptoms disappeared after 10 days and a diagnosis of Puumala infection
was made retrospectively on a serological basis. The case illustrates that anti-TNF treatment does not
worsen the course of Puumala infection and could even be associated with a milder clinical picture.
© 2010 Elsevier B.V. All rights reserved.
1. Why this case is important
The number of cases of Hantavirus infection is sharply increas-
ing. InWesternEurope, thePuumala serotype (PUUV) is responsible
for more than 10,000 cases of hemorragic fever with renal syn-
drome (HFRS) every year.1 Documented cases of acute PUUV
infection are usually very symptomatic: renal symptoms (olig-
uria and anuria) occur in more than 50% of the cases and
creatinin is increased in more than 90%. Hemorrrhagic manifes-
tations are uncommon but thrombocytopenia occurs in 55–70%
of the cases. Cardiac, ocular and neurological abnormalities have
also been reported in more than 50% of cases.2,3 The severity
of the symptoms can vary greatly between individuals but the
genetic factors involved remain controversial. HLA-B27 is asso-
ciated with a benign course of the disease, with minimal renal
involvement.4 Conversely, the ancestral HLA-B8 DR3 haplotype
has been shown to be associated with more severe forms of the
infection in adults.5 This haplotype is also more frequently found
in children with Puumala infection than in the general popu-
lation but it is not associated with a different clinical course.6
Interestingly, the HLA-B8 DR3 haplotype is in linkage desiquilib-
rium with an allele of the TNF- gene associated with a higher
secretion of TNF- (the so-called TNF-2 allele). Accordingly, Kan-
erva et al. found the TNF-2 allele more frequently in patients
hospitalized for acute PUUV infection (42%) than in healthy con-
∗ Corresponding author. Tel.: +32 43667235.
E-mail address: Michel.Moutschen@ulg.ac.be (M. Moutschen).
trols (15%).7 Similar ﬁndings were reported by Makela et al.8 In
a subsequent study, Makela et al. compared the severity of dis-
ease in HLA-B8DR3 negative patients with or without the TNF-2
allele and could not ﬁnd any difference, suggesting that a higher
TNF- secretion does not by itself plays a major role in severe
Puumala infection.9 Finally, Maes et al. showed that patients with
the GA-238 allele of the TNF- gene and considered to be low
TNF producers had a more severe clinical form of Puumala Han-
tavirus infection than high TNF producers.10 In view of these
controversies around TNF- genetics in susceptibility to Puumala
severe infection, we found interesting to describe the case of
adult patient on anti-TNF therapy for more than eight months
and developing a PUUV hantavirus infection with fever as the sole
symptom
2. Case description
The patient is an 18 yrs. Old Caucasian male. He declared bilat-
eral sacroiliitis in 2008. HLA-B27 was absent. At that time, he
was simply treated with non-steroidal anti-inﬂammatory drugs.
In September 2009, he developed acute terminal ileitis that led to a
diagnosis ofCrohn’sdiseaseafter surgery.After surgery, he received
a maintenance treatment with bimonthly injections of inﬂiximab
with complete resolution of articular and gastro-intestinal symp-
toms. Due to cutaneous reactions, inﬂiximab was replaced by
adalimumab in February 2010. The treatment was well tolerated
and the patient totally asymptomatic. InMay 2010, the patient pre-
sented vesperal peaks of fever between38 and39 ◦C.Hehad strictly
no other symptoms and could normally attend his classes at high
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school. Since he was treated with anti-TNF medications, he was
considered as risk for severe occult infection and a complete work-
upwas performed. Physical examinationwas strictly normal. Blood
analysis showed only an increased CRP at 98mg/L (N<6mg/L).
Leucocytes and formula were normal. Platelets were normal at
190,000/l. Urea was at 0.26g/L and serum creatinine at 10.5mg/L.
Liver function was normal. Except for CRP, all these values were
identical to those measured three months earlier on a routine anal-
ysis. Serologies for EBV and CMV were negative for IgM as well for
IgG. Blood cultures were performed several times and remained
negative including for mycobacteria. Chest X Ray was strictly nor-
mal as well as transesophageal echocardiogram. A PET/CT scanning
was even performed and was strictly normal exceptfor a moder-
ately increased glucose uptake in the distal ileon and ascending
colon. Fever spontaneously subsided after 10 days. The diagnosis
ﬁnally came out a few days later. In the context of an ongoing epi-
demy in our region, serum had been sent to an external reference
laboratory (Institute of Tropical Medicine, Antwerp) for Hantavirus
serology. IgMwere positive for Puumala andHantaan and IgGwere
negative for both serotypes. Fourweeks later, serologywas checked
again and showed the appearance of IgG speciﬁcally directed
against the Puumala serotype. Retrospectively, the patient recol-
lected that three weeks before the onset of fever he had cleaned
an old wood cabin in a wooded area. In view of the total absence
of urinary or renal symptoms, there was unfortunately no urine
analysis performed at the acute phase. When the diagnosis of han-
tavirus infection came out, urinary protein, 1-microglobulin and
2-microglobulin excretions were measured. They were strictly
normal.
Other similar and contrasting cases in the literature
To our knowledge, the clinical course of a hantavirus infection
in a patient under anti-TNF or other immunosuppressive therapy
has never been described before.
3. Discussion
Several articles have shown increased levels of pro-
inﬂammatory cytokines during hantavirus infection and correlated
them with the severity of the symptoms.11–14 On the other hand,
it has been shown that TNF- decreases the accumulation of viral
nucleoproteins in Vero E6 cells infected with Sin Nombre virus.15
Accordingly, hantavirus nucleocapsid proteins antagonize the
signaling pathway of TNF-, suggesting that this cytokine may
play a role in the immune response against hantavirus.16 Our
patient was only brieﬂy exposed to contaminated aerosols and
became infected while other members of his family had similar
activities without clinical evidence for infection. It it therefore
possible that TNF- treatment has been a risk factor for infection.
Nevertheless, the mild clinical course and the total absence of
renal or hematologic involvement suggest that TNF- is not
required for the clearance of infection and might furthermore
play a deleterious role in its manifestations (although we cannot
formally rule out a protective genetic background despite the
fact that the patient is not HLA-B27). Corticosteroids have been
used to treat severe complications of hantavirus infection.17 In
view of the crucial role of T cells secreting IFN- in the reso-
lution of the disease,18 amore targeted approachagainst TNF-
might be an option for severe hemorragic fever with renal
syndrome.
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